Approach to the patient: Contraception in women with polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages 794-802

  Yildiz, Bulent O ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; AGE; ARTERY THROMBOSIS; CARDIOMETABOLIC RISK; CASE REPORT; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CONTRAINDICATION; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GLUCOSE INTOLERANCE; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LONG TERM CARE; LOW DRUG DOSE; MEDICAL HISTORY; MORBID OBESITY; OLIGOMENORRHEA; ORAL CONTRACEPTION; ORAL CONTRACEPTIVE USE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; YOUNG ADULT; CONTRACEPTION; MENSTRUATION DISTURBANCES; PERSONALIZED MEDICINE; POLYCYSTIC OVARY SYNDROME; PROCEDURES;

CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HIRSUTISM; HUMANS; INDIVIDUALIZED MEDICINE; MENSTRUATION DISTURBANCES; POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 84924966184     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3196     Document Type: Review

References (46)

1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific Publications; 1992:377-384.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.
3. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society Guideline. J Clin Endocrinol Metab. 2006;91:4237-4245.
4. National Institutes of Health. Final Report of Evidence-based Methodology Workshop on Polycystic Ovary Syndrome, December 3-5, 2012. https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf.
5. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28-38.e25.
6. Yildiz BO. Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment. Semin Reprod Med. 2008;26:111-120.
7. Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27:3-12.
8. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27:13-24.
9. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12:169-178.
10. ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update. 2005;11:513-525.
11. Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004;89:1592-1597.
12. Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013;87:358-362.
13. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;1:CD003987.
14. World Health Organization. Medical eligibility criteria for contraceptive use. 2009. http://whqlibdoc.who.int/publications/2010/9789241563888-eng.pdf.
15. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010. Morbidity and Mortality Weekly Report. Recommendations and Reports. 2010;59(RR04):1-6.
16. Yildiz BO. Assessment, diagnosis and treatment of a patient with hirsutism. Nat Clin Pract Endocrinol Metab. 2008;4:294-300.
17. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2013;98:4565-4592.
18. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6:632-637.
19. Martinelli I. Counselling women about hormonal therapy. Thromb Res. 2009;123(suppl 2):S74-S78.
20. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921.
21. Crook D. Do different brands of oral contraceptives differ in their effects on cardiovascular disease? Br J Obstet Gynaecol. 1997;104:516-520.
22. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1575-1582.
23. Martínez F, Ramírez I, Pérez-Campos E, Latorre K, Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2012;17:7-29.
24. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013;347:f5298.
25. de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3:CD010813.
26. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013;27:25-34.
27. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002;87:3871-3875.
28. Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. Am J Obstet Gynecol. 2012;207:377.e1-e8.
29. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185:E115-E120.
30. ESHRE Capri Workshop Group. Venous thromboembolism in women: a specific reproductive health risk. Hum Reprod Update. 2013;19:471-482.
31. Khader YS, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception. 2003;68:11-17.
32. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257-2266.
33. Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertil Steril. 2006;85:1425-1431.
34. Troisi RJ, Cowie CC, Harris MI. Oral contraceptive use and glucose metabolism in a national sample of women in the United States. Am J Obstet Gynecol. 2000;183:389-395.
35. Chasan-Taber L, Willett WC, Stampfer MJ, et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care. 1997;20:330-335.
36. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014;4:CD006133.
37. Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab. 1997;82:3074-3077.
38. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000;15:1266-1274.
39. Halperin IJ, Kumar SS, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod. 2011;26:191-201.
40. Falsetti L, Pasinetti E. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 1995;74:56-60.
41. Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf). 1999;50:517-527.
42. Mes-Krowinkel MG, Louwers YV, Mulders AG, de Jong FH, Fauser BC, Laven JS. Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertil Steril. 2014;101:1757-1765.e1.
43. Ibáñez L, Díaz M, Sebastiani G, Marcos MV, López-Bermejo A, de Zegher F. Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity. J Clin Endocrinol Metab. 2013;98:E902-E907.
44. Harmanci A, Cinar N, Bayraktar M, Yildiz BO. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2013;78:120-125.
45. Verhaeghe J. Hormonal contraception in women with the metabolic syndrome: a narrative review. Eur J Contracept Reprod Health Care. 2010;15:305-313.
46. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care. 1999;4:67-73.